Trial Condition(s):
Therapeutic Equivalency, Biological Availability, Postmenopause
Study to investigate the bioequivalence and bioavailability of different formulations containing 0.030 mg Ethinylestradiol and 0.125 mg Levonorgestrel in postmenopausal women
Bayer Identifier:
91340
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations |
|---|
Trial Design
Open-label, randomized, crossover study to investigate the bioequivalence of two different tablet formulations containing 0.030 mg ethinylestradiol and 0.125 mg levonorgestrel (with gelatin [SH D00133A] versus gelatinfree [SH D00342A]) and to compare the bioavailability of the gelatincontaining formulation to that of a microcrystalline suspension [SH M00133A] in healthy postmenopausal women
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
